Welcome to our dedicated page for Biodesix news (Ticker: BDSX), a resource for investors and traders seeking the latest updates and insights on Biodesix stock.
Biodesix, Inc. (BDSX) is a trailblazing diagnostic solutions company specialized in the development and commercialization of blood-based molecular diagnostic tests. These tests advance the standard of care in oncology by providing invaluable data to help patients and their doctors make more informed decisions based on a patient's unique molecular profile. This approach is at the heart of precision medicine, aiming to provide the right treatment to the right patient at the right time.
The company is particularly focused on lung disease and operates in a single segment dedicated to providing diagnostic testing services. Biodesix partners with pharmaceutical companies to develop and commercialize diagnostic tests that accelerate drug development pipelines and bring effective therapies to the market.
Among its notable products are two commercialized tests, VeriStrat® and GeneStrat™, which offer rapid results within 72 hours and do not require tissue samples. These tests enable quicker and more precise treatment decisions, facilitating optimal patient care.
Biodesix's revenue streams come from two primary sources: providing diagnostic testing services related to blood-based lung and COVID-19 tests, and offering biopharmaceutical companies services for diagnostic research, clinical trial testing, and companion diagnostics development. These services are generally performed outside the clinical setting and are governed by individual contracts with third parties.
Recently, Biodesix has been in the news for various significant developments. The latest updates highlight the company's ongoing projects, partnerships, and achievements in the diagnostic field. Stay tuned for more updates as Biodesix continues to innovate in precision medicine and diagnostic solutions.
Biodesix (NASDAQ: BDSX) reported Q3 2024 financial results with revenue growing 35% year-over-year to $18.2 million. Lung Diagnostic revenue increased 40% to $17.2 million, while Biopharmaceutical Services revenue decreased 17% to $1.0 million. The company achieved a gross profit margin of 77.0%, up from 76.1% in Q3 2023. Net loss improved by 6% compared to Q3 2023. Lung Diagnostic test volume grew 34% to 13,900 tests. The company reiterated its 2024 revenue guidance of $70-72 million and expects to achieve Adjusted EBITDA profitability in H2 2025.
Biodesix (Nasdaq: BDSX), a diagnostic solutions company specializing in lung disease, has announced its participation in three upcoming investor conferences in New York this November. CEO Scott Hutton and CFO Robin Cowie will attend the Craig-Hallum Alpha Select Conference on November 19, the Wolfe Research Healthcare Conference on November 20, and the Canaccord Genuity Medtech, Diagnostics and Digital Health & Services Forum on November 21.
The company will deliver a presentation at the Canaccord event at 1:00 PM ET, which will be available via webcast on the Biodesix website's Investors section under 'News & Events'.
Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company focusing on lung disease, has announced its plans to release financial results for the third quarter ended September 30, 2024. The results will be published before trading begins on Friday, November 1, 2024. Following the release, Biodesix management will host a conference call and webcast at 8:30 a.m. Eastern Time on the same day to discuss the financial results and provide a general business update.
Interested parties can register for the webcast through a provided link. Analysts wishing to participate in the question and answer session should use a separate link. A replay of the webcast will be made available on the company's investor website approximately two hours after the call concludes. Participants are advised to join the call 15 minutes before the start time.
Biodesix (Nasdaq: BDSX) announced new data presentation at CHEST 2024 Annual Meeting and launch of a complementary clinical study. The presentation will showcase the use of Nodify Lung® Nodule Risk Assessment in over 35,000 patients in real-world settings. Dr. Kathryn Long will present findings on reclassification rates for lung cancer risk, highlighting how the tests help clarify diagnostic plans.
Additionally, Biodesix introduced the CLARIFY study, a retrospective chart review of up to 4,000 patients, aimed at confirming the performance of Nodify CDT® and Nodify XL2® tests in diverse patient subgroups. This study will expand evidence supporting Nodify Lung testing's validation and utility.
CEO Scott Hutton emphasized the impact of Nodify Lung testing on lung nodule risk characterization over the past four years. The CHEST conference will also feature a presentation on patient impact and case studies by Drs. Sonali Sethi and D. Kyle Hogarth.
Biodesix (Nasdaq: BDSX), a leading diagnostic solutions company focusing on lung disease, has announced its participation in two upcoming investor conferences in September 2024. The company's management team will be presenting at:
1. Lake Street Capital Markets 8th Annual Best Ideas Growth Conference on September 12, 2024, at The Yale Club in New York, NY. CEO Scott Hutton will be presenting.
2. Colorado BioScience Association (CBSA) Rocky Mountain Life Sciences Investor and Partnering Conference from September 12-13, 2024, at Beaver Run Resort & Conference Center in Breckenridge, CO. CFO Robin Cowie will be presenting.
These presentations offer opportunities for investors to gain insights into Biodesix's operations, strategies, and potential growth prospects in the diagnostic solutions sector, particularly in lung disease diagnostics.
Biodesix (NASDAQ: BDSX) reported strong Q2 2024 results, with revenue growing 51% year-over-year to $17.9 million. The company's gross profit margin improved to 78.4%, up 5.7% from Q2 2023. Biodesix raised its full-year 2024 revenue guidance to $70-72 million from $65-68 million. Q2 2024 saw improvements in net loss (19%) and Adjusted EBITDA (38%) compared to Q2 2023. Lung Diagnostic test volume grew 42% year-over-year to 13,900. The company's cash position strengthened to $42.2 million, bolstered by a $55 million offering. Biodesix continues to focus on its five on-market lung diagnostic tests and improving profitability.
Biodesix (Nasdaq: BDSX), a leading diagnostic solutions company focusing on lung disease, has announced its participation in Canaccord Genuity's 44th Annual Growth Conference. The event is scheduled for August 13-14, 2024, at the InterContinental Boston, MA.
CEO Scott Hutton will represent Biodesix in a fireside chat on Wednesday, August 14, 2024, at 1:00 PM ET. Additionally, the company will host in-person 1x1 investor meetings during the conference. Investors and interested parties can access a live webcast of the presentation through the 'News & Events' section of Biodesix's website, with a replay option available afterwards.
This participation underscores Biodesix's commitment to engaging with the investment community and showcasing its advancements in lung disease diagnostics.
Biodesix (Nasdaq: BDSX), a leading diagnostic solutions company, has announced it will release its second quarter 2024 financial results on August 7, 2024, after the market closes. The company will host a conference call and webcast at 4:30 p.m. Eastern Time on the same day to discuss the results and provide a general business update. Interested parties can register for the webcast online, and analysts wishing to participate in the Q&A session should use a separate link. A replay of the webcast will be available on Biodesix's investor website approximately two hours after the call concludes. Participants are advised to join 15 minutes before the start time.
Biodesix (Nasdaq: BDSX) has been named to Inc. Magazine’s 2024 Best Workplaces list. The accolade results from an in-depth, data-driven process identifying American companies with exceptional workplace cultures. Biodesix, a diagnostic solutions leader, was one of 543 honorees selected from thousands of submissions. The recognition follows a comprehensive employee survey by Quantum Workplace, focusing on management effectiveness, perks, recognition, and overall culture. Founded in 2006, Biodesix reported high double-digit revenue growth and a 93% employee engagement score. CEO Scott Hutton emphasized the company's commitment to a culture of excellence.
Biodesix, a diagnostic solutions company specializing in lung disease, has announced its participation in two investor conferences in June 2024. CEO Scott Hutton will present at the William Blair 44th Annual Growth Stock Conference on June 4 in Chicago, IL, at 10:40 AM CT. He will also present at the Jefferies Global Healthcare Conference on June 6 in New York, NY, at 8:30 AM ET. Both presentations will be webcast live and available for replay in the Investors section of Biodesix's website.
FAQ
What is the current stock price of Biodesix (BDSX)?
What is the market cap of Biodesix (BDSX)?
What does Biodesix, Inc. specialize in?
What are some of Biodesix's key products?
How does Biodesix contribute to precision medicine?
What services does Biodesix provide to biopharmaceutical companies?
What are Biodesix's primary revenue sources?
How quickly can Biodesix's tests provide results?
Does Biodesix require tissue samples for its tests?
What recent achievements has Biodesix made?
Is Biodesix focused solely on oncology diagnostics?
What is the ticker symbol for Biodesix, Inc. on the stock market?
